Cytokinetics (CYTK) presented data from the Phase 1 study of CK-4021586, or CK-586. The study met its primary and secondary objectives to assess the safety, tolerability and pharmacokinetics of single and multiple oral doses of CK-586. The company said the data support the advancement of CK-586 to a Phase 2 trial in patients with heart failure with preserved ejection fraction which is expected to begin in fourth quarter, 2024.
"The results from this Phase 1 study replicate pre-clinical findings that show CK-586 directly reduces cardiac contractility at the level of the sarcomere. Importantly, CK-586 was observed to have a shallow and predictable PK/PD relationship and half-life that enables a once-daily fixed dosing regimen in patients with HFpEF," said Stuart Kupfer, Senior Vice President, Chief Medical Officer.
For More Such Health News, visit rttnews.com.
For comments and feedback: editorial@rttnews.com